Immune & Gut Health

Immune and gut health peptides address two deeply interconnected systems. The gastrointestinal tract houses approximately 70% of the body's immune tissue, and the integrity of the intestinal barrier — just a single cell layer thick — is a critical determinant of both local and systemic immune function. Peptides in this category work through several mechanisms: restoring thymic function and T-cell maturation, directly killing pathogens through antimicrobial action, regulating tight junction proteins that control gut permeability, and modulating inflammatory signaling cascades. The overlap between immune regulation and gut health is not incidental — it reflects the biological reality that these systems cannot be meaningfully separated.

The thymic peptides form a central pillar of this category. Thymosin Alpha-1 (Ta1) is the most clinically validated, approved in over 35 countries for conditions including hepatitis B and C, and used as an immune adjuvant in cancer immunotherapy. It enhances dendritic cell function, promotes T-cell differentiation, and restores immune surveillance in immunocompromised patients. Thymalin and Thymulin are related but distinct thymic peptides — Thymalin is a peptide bioregulator from Khavinson's framework extracted from calf thymus, while Thymulin (formerly called Facteur Thymique Serique) is a zinc-dependent nonapeptide that modulates T-cell function. All three thymic peptides are relevant to immunosenescence — the progressive decline of immune function with age driven largely by thymic involution.

LL-37 is the only human cathelicidin antimicrobial peptide, part of the innate immune system's first line of defense. It disrupts bacterial membranes, neutralizes endotoxins, and modulates inflammation — a rare combination of direct antimicrobial action and immune regulation. Larazotide (AT-1001) operates through a highly specific mechanism: it regulates zonulin-mediated tight junction opening in the intestinal epithelium, directly addressing the "leaky gut" phenomenon. It has been studied in clinical trials for celiac disease, making it one of the more clinically advanced gut-targeted peptides. BPC-157 and KPV cross over from the healing-recovery category with relevant activity here — BPC-157 for its gut-protective and cytoprotective effects, KPV for its potent anti-inflammatory action through NF-kB inhibition.

Suramin has a particularly interesting story in this category. Originally developed in 1916 as an anti-parasitic drug for African trypanosomiasis (sleeping sickness), it has been repurposed for research into purinergic signaling, autism spectrum disorder, and immune modulation. Its mechanism involves antagonism of purinergic receptors, which influence immune cell communication and inflammatory responses. The evidence base across this category varies significantly — from Thymosin Alpha-1's extensive clinical deployment to Suramin's preliminary repurposing research — and each compound should be evaluated on its own evidentiary merit.